Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
2024; Nature Portfolio; Volume: 30; Issue: 9 Linguagem: Inglês
10.1038/s41591-024-03115-2
ISSN1546-170X
AutoresDanijela Tatović, Ashish Marwaha, Peter Taylor, Stephanie Hanna, Kymberley Carter, WY Cheung, Stephen D. Luzio, Gareth Dunseath, Hayley Hutchings, Gail Holland, Steve Hiles, Greg Fegan, Evangelia Williams, Jennie H. M. Yang, Clara Domingo‐Vila, Emily Pollock, Muntaha Wadud, Kirsten A. Ward‐Hartstonge, Susie Marques-Jones, Jane Bowen‐Morris, Rachel Stenson, Megan K. Levings, John W Gregory, Timothy Tree, Colin Dayan, Evelien Gevers, Shankar Kanumakala, Sunil Nair, Chris Gardner, Michal Ajzensztejn, Christina Wei, Chris Mouditis, Fiona Campbell, James Greening, Emma Webb, Mimi Chen, Rakesh Amin, B. White, Ambika Shetty, C Bidder, Nicholas Conway, Amalia Mayo, Eleni Christakou, Kamila Sychowska, Yasaman Shahrabi, Maximilian Robinson, Simi Ahmed, Jan Dutz, Laura Cook,
Tópico(s)T-cell and B-cell Immunology
ResumoImmunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the management of T1D. Ustekinumab binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, targeting development of T helper 1 cells and T helper 17 cells (T
Referência(s)